BRIEF published on 11/20/2024 at 07:05, 1 year 9 months ago Innate Pharma unveils its financial calendar for 2025 Annual Results Innate Pharma Financial Calendar 2025 Assemblies And Publications Euronext And Nasdaq Contribution
PRESS RELEASE published on 11/20/2024 at 07:00, 1 year 9 months ago Informations privilégiées / Autres communiqués Innate Pharma publie son calendrier financier pour 2025 incluant les dates de publication des résultats et de l'assemblée générale, visant à informer les investisseurs et actionnaires Immunothérapie Événements Financiers Innate Pharma Biotechnologies Calendrier Financier 2025
PRESS RELEASE published on 11/20/2024 at 07:00, 1 year 9 months ago Inside Information / Other news releases Innate Pharma releases its 2025 financial calendar including key publication dates for financial statements and shareholder meetings Financial Statements Investors Financial Calendar 2025 Innate Pharma
BRIEF published on 11/08/2024 at 07:05, 1 year 10 months ago Innate Pharma présente ses innovations en oncologie au SITC 2024 Immunothérapie Innate Pharma NK Cell Engager SITC 2024 Conjugué Anticorps-médicament
BRIEF published on 11/08/2024 at 07:05, 1 year 10 months ago Innate Pharma presents its innovations in oncology at SITC 2024 Immunotherapy Innate Pharma SITC 2024 NK Cell Engage Antibody-drug Conjugate
PRESS RELEASE published on 11/08/2024 at 07:00, 1 year 10 months ago Informations privilégiées / Autres communiqués Annonce de Innate Pharma sur les présentations de données de son portefeuille innovant en oncologie sélectionnées pour le congrès annuel du SITC 2024 Immunothérapie Oncologie ADC Innate Pharma SITC 2024
PRESS RELEASE published on 11/08/2024 at 07:00, 1 year 10 months ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
PRESS RELEASE published on 09/12/2024 at 13:09, 2 years ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 06/17/2024 at 07:05, 2 years 2 months ago Innate Pharma dévoile des résultats prometteurs pour le SAR443579/IPH6101 dans des cancers du sang Sanofi Innate Pharma SAR443579 Leucémie Cancer Du Sang
BRIEF published on 06/17/2024 at 07:05, 2 years 2 months ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
Published on 09/12/2026 at 02:35, 11 hours 40 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 15 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 10 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 50 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 15 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 45 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 5 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 31 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
